Commercial
How to partner with Qvin.
Three tracks. Academic and clinical research collaborations. Industry assay co-development. And — for philanthropic funders, strategic industry counterparties, and investors — a gated brief at background.qvin.com that goes substantially deeper than this site.
Where to start
Pick the path that fits.
Research partnerships
Academic institutions, clinical research groups, and consortium-based programs.
Industry partnerships
Assay co-development, platform translation, and regulator-track work with diagnostic and life-sciences companies.
Investor & strategic
Philanthropic funders, industry counterparties exploring deals, investors evaluating in depth — go to background.qvin.com.
Research partnerships
For academic institutions and clinical research groups.
Qvin works alongside academic institutions and clinical research groups on women's-health programs — providing the collection device, the lab, and the analytical and regulatory infrastructure that gets a research idea from sample to publication and, when warranted, on to a regulator-cleared assay.
What we provide
- Q-Pad collection kits — FDA-cleared, CE- and UKCA-marked diagnostic menstrual pads, shipped at room temperature anywhere the postal system reaches.
- Qvin Labs services — accessioning, elution, and analysis of Dried Menstrual Samples on a CLIA-certified analytical pipeline; interpretation reports.
- Biobanking — long-term sample storage, retrieval, and chain-of-custody for longitudinal studies.
- Assay design support — translating a research question into a method that runs on DMS, with regulator-track viability where applicable.
- Regulatory know-how — pre-existing 510(k) clearance and analytical predicates accelerate downstream submissions for translational work.
Active collaborations
- Mayo Clinic — multi-program biomarker and clinical research work.
- University of Exeter (Wellcome Leap) — perimenopause biomarkers under Wellcome Leap's Missed Vital Sign program.
- Statens Serum Institut (CYCLOME) — Wellcome Leap–funded cyclical proteome and methylome characterization.
- Stanford University (iPOP) — multi-omic deep phenotyping using menstrual blood as a recurring sample.
How to get started
Email soren@qvin.com with a short summary of the research question, the population, and the expected sample volume. We follow with a scoping conversation and, when there's fit, a Material Transfer Agreement and study protocol.
Industry partnerships
Assay co-development and platform translation.
Qvin co-develops menstrual blood–based assays with diagnostic and life-sciences companies. The current most-advanced commercial collaboration is with a leading global molecular diagnostics player, focused on bringing HPV and STI detection to a self-collection screening model on a regulator-cleared analyzer platform. Material Transfer Agreements protect each party's assets, and relationships are structured without exclusivity lock-in.
Typical engagement shapes
- Assay translation — porting an existing analyzer-based assay onto Dried Menstrual Samples; analytical bridging and regulatory submission planning.
- Platform partnership — joint commercialization of a Q-Pad-collected menu on a partner's analytical platform; revenue share or royalty structures.
- Discovery collaboration — pharma-funded biomarker discovery for a therapeutic program, leveraging recurring at-home menstrual sampling.
- Trial-grade collection — Q-Pad-based decentralized sample collection for clinical trials and post-market studies.
How to get started
Industry partnership inquiries: soren@qvin.com. For substantive evaluation, expect to be invited to background.qvin.com, where strategic, regulatory, and IP detail is documented in depth.
Background
For philanthropic, industry, and investor inquiries.
Philanthropic funders, strategic industry counterparties, and investors evaluating Qvin in depth are pointed to a private, gated brief at background.qvin.com. It is the company explained for serious counterparties — strategy, market analysis, regulatory know-how, IP detail, manufacturing depth, the team in depth, and the strategic exit case.
How access works
Visit background.qvin.com, click Request access, and tell us who you are and what you're evaluating. Requests are reviewed within a few business days. Access is granted via Google Sign-In or an email magic link tied to a verified work address.
Contact
Direct contact.
For anything not covered above — press inquiries, careers, general questions — write to hello@qvin.com. For founder-level conversations on partnerships and strategic relationships: soren@qvin.com.